DTC spend declined in third quarter

Could DTC be going the way of detailing?

DTC spending declined 7.1% in the third quarter—the first decline in recent memory—to $1.125 billion as companies pruned print, radio and network TV advertising, according to Nielsen Media Research data.

While network TV ad spend dipped for the quarter, year-on-year—from $332 million to $304 million—spending on cable TV rose, from $275 million to $288 million, as did spending on syndicated, spot and Spanish language TV. National magazine ad spend slid from $330 million to $300 million, while national Sunday supplement spend dropped from $36 million to $18 million and local newspaper spend plummeted from $2 million to $725,817. Network radio spend skidded from $6.3 million to $3.5 million, and spot radio spend went from $6.6 million to just over $1 million.

Spend on AstraZeneca's Crestor dropped from $43 million for Q3 2006 to $4 million for Q3 2007, while Nexium spend went from $43 million to $17 million. Pfizer's support for Lipitor slipped from $31 million to $23 million, and Relpax went from $18 million to nothing. The sleep category saw incremental increases in spend, with exception to Takeda's Rozerem, which ratcheted down from $58 million to $32 million. Novartis dropped support for Lamisil and Zelnorm, which together accounted for $60 million in Q3 spend in 2006. Similarly, GlaxoSmith-

Kline dropped support for Imitrex and Coreg, for which it laid out $44 million combined in Q3 2006. Lilly trimmed Cymbalta's sails from $39 million for Q3 2006 to $26 million in 2007.

Those declines were offset by launch campaigns and heightened spend on drugs like Cialis, Abilify, Nasonex and Plavix.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions